RecruitingPhase 3NCT07038200
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Studying Facioscapulohumeral dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Avidity Biosciences, Inc.
- Intervention
- AOC-1020(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 16-70 years · All sexes
- Timeline
- 2025 – 2028
Study locations (22)
- University of California Irvine, Orange, California, United States
- Stanford University, Palo Alto, California, United States
- University of Colorado, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- Kansas University Medical Center, Kansas City, Kansas, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- University of Massachusetts, Worcester, Massachusetts, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Duke University, Durham, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- University of Calgary - Cumming School of Medicine, Calgary, Alberta, Canada
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07038200 on ClinicalTrials.govOther trials for Facioscapulohumeral dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07086521Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)Restem, LLC.
- RECRUITINGPHASE1, PHASE2NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyEpicrispr Biotechnologies, Inc.
- ENROLLING BY INVITATIONNCT07164937Imaging and Gait Analysis in FSHD PatientsFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06911190Ten Year Follow-up in FSHD: the FOCUS 3 StudyRadboud University Medical Center
- RECRUITINGNCT07409142BetterLife FSHD: A Patient-driven Health and Research PlatformFSHD Society
- ENROLLING BY INVITATIONPHASE2NCT06547216Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)Avidity Biosciences, Inc.
- RECRUITINGNANCT06600308Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular DystrophiesCentre Hospitalier Universitaire Dijon
- ACTIVE NOT RECRUITINGPHASE2NCT06222827Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1Centre Hospitalier Universitaire de Nice